AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-1.45%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$635M
AUM Growth
+$635M
(+3.2%)
Cap. Flow
+$13M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
39.19%
Holding
115
New
23
Increased
29
Reduced
18
Closed
15
Top Buys
| 1 |
Alkermes
ALKS
|
$13.9M |
| 2 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$11.9M |
| 3 |
Apogee Therapeutics
APGE
|
$9.61M |
| 4 |
Arcellx
ACLX
|
$8.83M |
| 5 |
Insmed
INSM
|
$8.38M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$45.4M |
| 2 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$10.6M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$9.7M |
| 4 |
Absci
ABSI
|
$5.82M |
| 5 |
Cytokinetics
CYTK
|
$5.61M |
Sector Composition
| 1 | Healthcare | 89.38% |
| 2 | Financials | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $38.8M | 4.47% | 994,227 +156,840 | +19% | +$6.12M |
|
|
2
Apogee Therapeutics
APGE
$2.17B
| $32.9M | 3.79% | 836,283 +244,190 | +41% | +$9.61M |
|
3
Madrigal Pharmaceuticals
MDGL
$9.76B
| $30.8M | 3.55% | 110,000 -5,000 | -4% | -$1.4M |
|
|
4
Arcellx
ACLX
$3.85B
| $25.4M | 2.93% | 460,000 +160,000 | +53% | +$8.83M |
|
5
Teva Pharmaceuticals
TEVA
$21.1B
| $23.6M | 2.72% | 1,450,000 +50,000 | +4% | +$813K |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $23.1M | 2.66% | 515,000 +45,000 | +10% | +$2.02M |
|
|
CERE
7
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $20.4M | 2.36% | 500,000 +200,000 | +67% | +$8.18M |
|
8
Nurix Therapeutics
NRIX
$714M
| $19M | 2.19% | 912,000 +101,747 | +13% | +$2.12M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $17.6M | 2.03% | 475,400 -34,600 | -7% | -$1.28M |
|
|
ONC
10
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $15.7M | 1.81% | 110,000 +27,857 | +34% | +$3.97M |
|
|
11
Alkermes
ALKS
$4.78B
| $15.7M | 1.81% | 650,000 +575,000 | +767% | +$13.9M |
|
12
Nuvalent
NUVL
$5.52B
| $15.2M | 1.75% | 200,000 +50,000 | +33% | +$3.79M |
|
|
AUTL
13
Autolus Therapeutics
AUTL
$399M
| $15M | 1.72% | 4,300,000 +925,000 | +27% | +$3.22M |
|
14
Vera Therapeutics
VERA
$1.38B
| $13.6M | 1.56% | 375,000 -95,000 | -20% | -$3.44M |
|
15
Kura Oncology
KURA
$686M
| $13.4M | 1.54% | 650,000 -80,492 | -11% | -$1.66M |
|
|
INZY
16
DELISTED
Inozyme Pharma
INZY
| $12.7M | 1.47% | 2,856,252 +213,733 | +8% | +$953K |
|
17
Spyre Therapeutics
SYRE
$996M
| $12.1M | 1.39% | 513,420 +103,420 | +25% | +$2.43M |
|
|
CLYM
18
Climb Bio, Inc. Common Stock
CLYM
$151M
| $11.9M | 1.37% | +1,670,661 | New | +$11.9M |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.25B
| $10.3M | 1.18% | 1,135,702 +305,156 | +37% | +$2.76M |
|
20
Establishment Labs
ESTA
$1.2B
| $10.2M | 1.17% | 223,407 +58,818 | +36% | +$2.67M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $10.1M | 1.17% | 700,000 -117,833 | -14% | -$1.7M |
|
|
NARI
22
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $9.63M | 1.11% | 200,000 +25,000 | +14% | +$1.2M |
|
23
Immunovant
IMVT
$2.56B
| $9.14M | 1.05% | 346,088 +61,088 | +21% | +$1.61M |
|
24
Astria Therapeutics
ATXS
$349M
| $8.88M | 1.02% | 975,606 +130,000 | +15% | +$1.18M |
|
|
MORF
25
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.54M | 0.98% | 250,573 +25,573 | +11% | +$871K |
|